ClinicalTrials.gg
CompletedNCT00289887Updated Feb 9, 2022Results posted

Obese Hypertension Study (0954-315)

A Phase 3 interventional study of Comparator: losartan +/- HCTZ and Comparator: Placebo in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Enrollment
17th of 65
261 · median 100
Started
2006
with 2 others
Phase 3
17 of 65
1 open now
Registered
6th of 65
by date
Lead sponsor
7 of 65
Organon and Co

Among the 65 studies testing losartan in Hypertension, this one is the 17th largest by enrollment, is one of 3 that started in 2006, is one of 17 in phase 3, and was the 6th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

This is a 16-week study to evaluate high systolic and diastolic blood pressure following treatment in obese, hypertensive, adult patients.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Obese male and female patients, ages 21-75 years, with high blood pressure

Exclusion criteria

Exclusion Criteria:

  • Patients cannot have any other severe cardiac conditions
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
261 participants (actual)

Study arms

  • Experimental
    1

    Losartan

    Drug: Comparator: losartan +/- HCTZ

  • Placebo comparator
    2

    Placebo

    Drug: Comparator: Placebo

Interventions

  • DrugComparator: losartan +/- HCTZ

    Drug pages: Losartan · Hydrochlorothiazide

    Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.

  • DrugComparator: Placebo

    Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8

    Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 8. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

    Time frame: At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)

  2. Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8

    Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 8. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

    Time frame: At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)

  3. Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

    Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 12. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

    Time frame: At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)

  4. Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12

    Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 12. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

    Time frame: At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)

  5. Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 16

    Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 16. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

    Time frame: At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)

  6. Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 16

    Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 16. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

    Time frame: At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)

07

Results

Posted May 27, 2010

Participant flow

Patients were recruited at 51 sites in the United States. Prime Therapy Period: April 2006 to February 2007

Participant flow — Overall Study
MilestoneLosartanPlacebo
Started127134
Completed105105
Not completed2229
Withdrew: Adverse event33
Withdrew: Lack of efficacy311
Withdrew: Lost to follow-up33
Withdrew: Protocol violation31
Withdrew: Withdrawal by subject38
Withdrew: Other73

Outcome measures

PrimaryMean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8

Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 8. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

Time frame:
At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Reported as:
Least squares mean · mm Hg
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8
mm HgLosartanPlacebo
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8-12.1 ± 1.2-6.8 ± 1.2
PrimaryMean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8

Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 8. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

Time frame:
At baseline and at 8 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Reported as:
Least squares mean · mm Hg
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8
mm HgLosartanPlacebo
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 8-9.7 ± 0.8-6.9 ± 0.8
PrimaryMean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12

Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 12. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

Time frame:
At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Reported as:
Least squares mean · mm Hg
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
mm HgLosartanPlacebo
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12-12.9 ± 0.8-7.1 ± 0.8
PrimaryMean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12

Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 12. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

Time frame:
At baseline and at 12 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Reported as:
Least squares mean · mm Hg
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12
mm HgLosartanPlacebo
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12-16.7 ± 1.3-6.8 ± 1.3
PrimaryMean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 16

Mean change from baseline in trough (6 hours after last morning dose) SiSBP at Week 16. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

Time frame:
At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Reported as:
Least squares mean · mm Hg
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 16
mm HgLosartanPlacebo
Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 16-19.1 ± 1.3-6.4 ± 1.3
PrimaryMean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 16

Mean change from baseline in trough (6 hours after the last morning dose) SiDBP at Week 16. A mixed effects model (with repeated measurements including terms of treatment, investigators, week, baseline SiSBP(/SiDBP), plasma glucose stratum, treatment\*week, and week\*SiSBP(/SiDBP)) was used to compare the treatments on the change from baseline.

Time frame:
At baseline and at 16 weeks (with the measurements taken prior to the morning dose, between 6 AM and 10 AM)
Reported as:
Least squares mean · mm Hg
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 16
mm HgLosartanPlacebo
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 16-14.1 ± 0.9-6.0 ± 0.9

Adverse events

Collected over Week 0 through Week 16.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Losartan—1/127 (0.8%)4/127 (3.1%)
Placebo—1/134 (0.7%)7/134 (5.2%)
Most frequent serious events
Most frequent serious events
EventLosartanPlacebo
Pancreatitis acuteGastrointestinal disorders1/1270/134
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1271/134
Most frequent other events
Most frequent other events
EventLosartanPlacebo
HeadacheNervous system disorders4/1277/134

Baseline characteristics

Age, Continuous
Age, Continuous(years)LosartanPlaceboTotal
Mean50.1 ± 10.451.4 ± 9.750.8 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)LosartanPlaceboTotal
Female7977156
Male4857105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)LosartanPlaceboTotal
Caucasian8487171
Black222951
Hispanic American201636
Native American011
Other112
Sitting Diastolic Blood Pressure (SiDBP)
Sitting Diastolic Blood Pressure (SiDBP)(mm Hg)LosartanPlaceboTotal
Mean99.1 ± 4.299.0 ± 4.099.0 ± 4.1
Sitting Systolic Blood Pressure (SiSBP)
Sitting Systolic Blood Pressure (SiSBP)(mm Hg)LosartanPlaceboTotal
Mean151.6 ± 8.2152.4 ± 9.0152.0 ± 8.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Oparil S, Abate N, Chen E, Creager MA, Galet V, Jia G, Julius S, Lerman A, Lyle PA, Pool J, Tershakovec AM. A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. Curr Med Res Opin. 2008 Apr;24(4):1101-14. doi: 10.1185/030079908x280716. Epub 2008 Mar 6. PubMed 18328120 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Feb 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2006
First posted
Feb 10, 2006
Start
Feb 2006
Primary completionActual
Feb 2007
CompletionActual
Mar 2007
Results first posted
May 27, 2010
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00289887
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Feb 10, 2006
Start date
Feb 2006
Primary completion
Feb 2007
Completion
Mar 2007
Results posted
May 27, 2010
Last update
Feb 9, 2022

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Losartan · Hydrochlorothiazide

Start the discussion